NCT06393387Completed
Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States
Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States (REVIVE Study)
Source: ClinicalTrials.gov · Last updated 26 Sept 2025
Brief summary (registry, in English)
This real-world retrospective study describes the clinical efficacy of 2DR (DOVATO® (DTG/3TC)) versus 3DR (BIKTARVY® (BIC/F/TAF)) in PWH, including those with at least 2 social determinants of health indicators, across a multi clinic infectious disease organization in the Southeast United States
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 800 (actual)
- First submitted
- 26 Apr 2024
- Start date
- 1 Jun 2024
- Primary completion date
- 1 Apr 2025
- Lead sponsor
- Midway Specialty Care Center
- Diseases
- HIV
- NCT number
- NCT06393387
What you commit to
- Study type: Observational
- Participants enrolled: 800
- From 1 Jun 2024 to the primary completion date, 1 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Index regimen is BIC/F/TAF and has a history of ART consisting of DTG+3TC or DTG/3TC;
- Index regimen is DTG/3TC and has a history of ART consisting of BIC/F/TAF
Who the study is looking for
- Adults, aged 18 years and older;
- Diagnosis of HIV-1;
- Have a history of ART consisting of DTG/3TC or BIC/F/TAF, initiated from May 1, 2019 through January 28, 2023;
- Have at least 48 weeks of clinical follow up after initiation of DTG/3TC or BIC/F/TAF; clinical follow-up can include time post-discontinuation of either index regimen;
- Complete data, for HIV-1 RNA viral load at all study time points, including baseline, through 24 weeks and through 48 weeks;
- Received care from a physician, nurse practitioner or physician assistant at the organization
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Midway Specialty Care Center Coordinator of this site? Confirm its status | West Palm Beach | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.